The National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) is the only adult cooperative oncology group based in Canada that has a national membership and is committed to assessing all modalities of therapy across the spectrum of different types of cancer. The Group was founded in 1980 through funding provided by the National Cancer Institute of Canada, which is the research arm of the Canadian Cancer Society (a charitable organization). Since 1980, the NCIC CTG has undergone substantial growth in its scope, membership, and clinical trials activities. This growth has included leadership by the NCIC CTG of large randomized controlled (phase III) clinical trials conducted in the United States in collaboration with the US-based cooperative groups that are funded by NCI/CTEP. In addition, the NCIC CTG is a principal mechanism by which Canadian patients are included in clinical trials led by these US-based groups. The purpose of this grant is to support these collaborative activities, which enhance the productivity of investigators in Canada and the US, and provide benefits to patients from both countries. The mission of the NCIC CTG is to demonstrate the efficacy and to assess the relative effectiveness of interventions that will prevent the development of cancer or will improve the care of patients who develop cancer. Goals included within this mission are to base our clinical trials on sound understandings of molecular biology and to include correlative biologic questions within these trials, as well as to evaluate endpoints that are relevant to patients and society, such as quality of life and analyses of health economics. To meet this goal requires international collaboration. The specific objectives of this grant are for NCIC CTG to collaborate with NCI/CTEP and US-based groups, including through the principles outlined in the Report of the Clinical Trials Working Group, to develop new Intergroup trials under NCIC CTG leadership and to ensure more rapid accrual to trials led by US-based groups, to enhance the scientific content of these trials through evaluation of additional endpoints and to contribute to new understandings of clinical trial methodology and analysis. The support requested is to provide funding for per-patient accrual and for personnel within the Central Office of the NCIC CTG in order that the organization can efficiently develop, activate and conduct in Canada trials that of importance to our collaborators in the United States.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
3U10CA077202-13S2
Application #
8538120
Study Section
Subcommittee G - Education (NCI)
Program Officer
Mooney, Margaret M
Project Start
1998-09-30
Project End
2013-07-31
Budget Start
2012-08-01
Budget End
2013-07-31
Support Year
13
Fiscal Year
2012
Total Cost
$1,390,686
Indirect Cost
$24,495
Name
Queen's University at Kingston
Department
Type
DUNS #
207884032
City
Kingston
State
ON
Country
Canada
Zip Code
K7 3-N6
Beltran, Himisha; Wyatt, Alexander W; Chedgy, Edmund C et al. (2017) Impact of Therapy on Genomics and Transcriptomics in High-Risk Prostate Cancer Treated with Neoadjuvant Docetaxel and Androgen Deprivation Therapy. Clin Cancer Res 23:6802-6811
Saha, Poornima; Regan, Meredith M; Pagani, Olivia et al. (2017) Treatment Efficacy, Adherence, and Quality of Life Among Women Younger Than 35 Years in the International Breast Cancer Study Group TEXT and SOFT Adjuvant Endocrine Therapy Trials. J Clin Oncol 35:3113-3122
Agarwala, Sanjiv S; Lee, Sandra J; Yip, Waiki et al. (2017) Phase III Randomized Study of 4 Weeks of High-Dose Interferon-?-2b in Stage T2bNO, T3a-bNO, T4a-bNO, and T1-4N1a-2a (microscopic) Melanoma: A Trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Gro J Clin Oncol 35:885-892
Sonnenblick, Amir; Agbor-Tarh, Dominique; Bradbury, Ian et al. (2017) Impact of Diabetes, Insulin, and Metformin Use on the Outcome of Patients With Human Epidermal Growth Factor Receptor 2-Positive Primary Breast Cancer: Analysis From the ALTTO Phase III Randomized Trial. J Clin Oncol 35:1421-1429
Ribi, Karin; Luo, Weixiu; Bernhard, Jürg et al. (2016) Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcomes in the Suppression of Ovarian Function Trial. J Clin Oncol 34:1601-10
Goss, Paul E; Ingle, James N; Pritchard, Kathleen I et al. (2016) Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years. N Engl J Med 375:209-19
Phillips, Kelly-Anne; Regan, Meredith M; Ribi, Karin et al. (2016) Adjuvant ovarian function suppression and cognitive function in women with breast cancer. Br J Cancer 114:956-64
Ribi, Karin; Bernhard, Jürg; Luo, Weixiu et al. (2016) Reply to F. Tomao et al. J Clin Oncol 34:4189-4190
Regan, Meredith M; Francis, Prudence A; Pagani, Olivia et al. (2016) Absolute Benefit of Adjuvant Endocrine Therapies for Premenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer: TEXT and SOFT Trials. J Clin Oncol 34:2221-31
Johansson, Harriet; Gray, Kathryn P; Pagani, Olivia et al. (2016) Impact of CYP19A1 and ESR1 variants on early-onset side effects during combined endocrine therapy in the TEXT trial. Breast Cancer Res 18:110

Showing the most recent 10 out of 73 publications